New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19
HASBROUCK HEIGHTS, NJ (October 19, 2011) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report on the podium presentation of new data on the long term safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) at the Annual Meeting of the North Central Section of the American Urological Association in Rancho Mirage, CA on October 19, 2011. Neal Shore MD FACS, the Medical Director of the Carolina Urologic Research Center and a highly experienced clinical trial investigator, reviewed the progress of the clinical trial program for NX-1207 to date and presented new analyses of long-term follow-up data for up to 6 ½ years after a single treatment with NX-1207.
According to the peer-reviewed abstract at the meeting, “Overall at 3 to 6 ½ years after a single treatment of NX- 1207, 37 to 55% of subjects required no surgical treatments or medication for their BPH. All Phase 2 follow-up study efficacy results reached statistical significance and there were no sexual side effects or significant adverse safety events attributable to study drug.” The authors of the abstract were Dr. Shore, Barrett Cowan MD FACS of Denver CO, Barton Wachs MD FACS of Long Beach CA, Chris Threatt MD of Atherton CA, Rafael Wurzel MD CPI of New Britain CT, Kevin Cline MD of Shreveport LA, and Sheldon Freedman MD FACS of Las Vegas NV.
Dr. Shore said, “Ongoing follow-up from prior trials of NX-1207 continues to demonstrate a favorable durability of effect”.
NX-1207 is currently being studied in two pivotal Phase 3 clinical trials, NX02-0017 and NX02-0018, being conducted at approximately 70 urology clinics across the U.S.
Completed Phase 2 clinical trials showed that a single administration of NX-1207 resulted in symptomatic improvements which reached statistical significance compared to double-blinded placebo and study controls.
Patient-reported improvements in the standardized BPH symptom score were on average 8 to 10 points at 90 days as compared to the approximately 3 to 5 points reported on average for currently approved BPH drugs. The drug is administered by a urologist in an office setting in a brief procedure that does not require anesthesia, sedation, or catheterization and involves little or no pain or discomfort. NX-1207 treatment has not been found to have the sexual, blood pressure, or other side effects associated with the use of the approved drugs for the treatment of BPH.
Follow-up studies of available subjects from the completed clinical trials have shown clinical benefits in terms of long term symptomatic improvement or reduced need for subsequent treatment for up to 7 years following a single NX-1207 treatment.
BPH is one of the most commonly diagnosed diseases in the male U.S. population. The condition can seriously impact the health and quality of life of older men and can lead to acute urinary retention, incontinence, and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
For Further Information Contact:
Nymox Pharmaceutical Corporation
Posted: October 2011